Literature DB >> 15748157

Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones.

Julian Bösel1, Florin Gandor, Christoph Harms, Michael Synowitz, Ulrike Harms, Pierre Chryso Djoufack, Dirk Megow, Ulrich Dirnagl, Heide Hörtnagl, Klaus B Fink, Matthias Endres.   

Abstract

Statins [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors] exert cholesterol-independent pleiotropic effects that include anti-thrombotic, anti-inflammatory, and anti-oxidative properties. Here, we examined direct protective effects of atorvastatin on neurones in different cell damage models in vitro. Primary cortical neurones were pre-treated with atorvastatin and then exposed to (i) glutamate, (ii) oxygen-glucose deprivation or (iii) several apoptosis-inducing compounds. Atorvastatin significantly protected from glutamate-induced excitotoxicity as evidenced by propidium iodide staining, nuclear morphology, release of lactate dehydrogenase, and mitochondrial tetrazolium metabolism, but not from oxygen-glucose deprivation or apoptotic cell death. This anti-excitototoxic effect was evident with 2-4 days pre-treatment but not with daily administration or shorter-term pre-treatment. The protective properties occurred independently of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition because co-treatment with mevalonate or other isoprenoids did not reverse or attenuate neuroprotection. Atorvastatin attenuated the glutamate-induced increase of intracellular calcium, which was associated with a modulation of NMDA receptor function. Taken together, atorvastatin exerts specific anti-excitotoxic effects independent of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition, which has potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748157     DOI: 10.1111/j.1471-4159.2004.02980.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  59 in total

1.  Effect of previous statin therapy on severity and outcome in ischemic stroke patients: a population-based study.

Authors:  Corine Aboa-Eboulé; Christine Binquet; Agnès Jacquin; Marie Hervieu; Claire Bonithon-Kopp; Jérôme Durier; Maurice Giroud; Yannick Béjot
Journal:  J Neurol       Date:  2012-06-24       Impact factor: 4.849

2.  The relationship between statin use and open-angle glaucoma.

Authors:  Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch
Journal:  Ophthalmology       Date:  2012-06-21       Impact factor: 12.079

3.  Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.

Authors:  Marc-Alexander L T Parent; David A Hottman; Shaowu Cheng; Wei Zhang; Lori L McMahon; Li-Lian Yuan; Ling Li
Journal:  Cell Mol Neurobiol       Date:  2014-04-01       Impact factor: 5.046

Review 4.  [Direct neuronal effects of statins].

Authors:  J Bösel; M Endres
Journal:  Nervenarzt       Date:  2006-03       Impact factor: 1.214

Review 5.  Statins and ischemic stroke severity: cytoprotection.

Authors:  Larry B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2009-07       Impact factor: 5.113

Review 6.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  The basal level of intracellular calcium gates the activation of phosphoinositide 3-kinase-Akt signaling by brain-derived neurotrophic factor in cortical neurons.

Authors:  Fei Zheng; Deborah Soellner; Joseph Nunez; Hongbing Wang
Journal:  J Neurochem       Date:  2008-05-12       Impact factor: 5.372

8.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices.

Authors:  Fabiana K Ludka; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra Celso Constantino; Caio Massari; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.590

9.  Atorvastatin in stroke: a review of SPARCL and subgroup analysis.

Authors:  Branko N Huisa; Andrew B Stemer; Justin A Zivin
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.